Drug Design Concepts for LSD1-Selective Inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Lysine-specific demethylase 1 (LSD1) is a flavin-dependent oxidase regulating histone H3 methylation.
• LSD1 is implicated in various diseases, including cancer, metabolic disorders, and psychiatric conditions, making it a key therapeutic target.
• Existing LSD1 inhibitors often lack sufficient potency and selectivity.

Purpose of the Study:

• To design and identify novel LSD1-selective inhibitors.
• To develop therapeutic agents targeting LSD1 for disease treatment.

Main Methods:

• Utilized target-guided synthesis strategies based on original drug design concepts.
• Evaluated inhibitor activity and selectivity for LSD1.
• Assessed bioactivities in vitro and in vivo.

Main Results:

• Identified several potent and selective LSD1 inhibitors.
• Demonstrated unique bioactivities of the developed inhibitors in both in vitro and in vivo models.
• Confirmed the efficacy of target-guided synthesis in discovering novel enzyme inhibitors.

Conclusions:

• The developed LSD1 inhibitors exhibit potent selectivity and significant bioactivities.
• These findings support LSD1 as a viable drug target and highlight the success of the employed drug design approach.
• The novel inhibitors represent promising candidates for treating LSD1-associated diseases.